Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 29, 2020
July 29, 2020
ad15136b-9f37-470e-a814-e84a9756a3ca
Related Documents
Premenopausal Women with Breast Cancer: Developing Drugs for Treatment: Guidance for Industry
Guidance DocumentJune 17, 2021Office of the Commissioner
Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry
Guidance DocumentJune 28, 2022Office of the Commissioner
Male Breast Cancer: Developing Drugs for Treatment: Guidance for Industry
Guidance DocumentAugust 12, 2020Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.